{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:47Z","timestamp":1792788467445,"version":"4.5.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Talent Fund of Guizhou Provincial People\u2019s Hospital","award":["[2024]-26"],"award-info":[{"award-number":["[2024]-26"]}],"id":[{"id":"https:\/\/ror.org\/046q1bp69","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00999-9","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:43:15Z","timestamp":1791528195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose radiotherapy as an immunomodulator in cancer: dose-specific mechanisms and hybrid high-dose\/low-dose strategies"],"prefix":"10.1186","volume":"14","author":[{"given":"Jingjing","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demiao","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qikun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejun","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liankui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"999_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.radonc.2021.06.037","volume":"162","author":"RR Patel","year":"2021","unstructured":"Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, et al. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021;162:60\u20137.","journal-title":"Radiother Oncol"},{"key":"999_CR2","doi-asserted-by":"crossref","unstructured":"Zhou L, Liu Y, Xing Z, Wu Y, Yang X, Chen S, Kang K, Wang M, Zhou Z, Huang M et al. Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming. Signal Transduct Target Ther. 2026;11(1):170.","DOI":"10.1038\/s41392-026-02712-6"},{"key":"999_CR3","doi-asserted-by":"crossref","unstructured":"Ji H, Zhou Z. A \u2018Hybrid\u2019 Radiotherapy regimen designed for immunomodulation: combining high-dose radiotherapy with low-dose radiotherapy. Cancers (Basel). 2022;14(14):3505.","DOI":"10.3390\/cancers14143505"},{"issue":"1","key":"999_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12967-025-06450-1","volume":"23","author":"G Lin","year":"2025","unstructured":"Lin G, Yao Z, Kang K, Luo R, Yi L, Lu Y. Dynamic evolution and antitumor mechanisms of CXCR6(+)CD8(+) T cells in small cell lung cancer treated with low-dose radiotherapy and immunotherapy. J Transl Med. 2025;23(1):453.","journal-title":"J Transl Med"},{"key":"999_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fonc.2015.00087","volume":"5","author":"L Gorchs","year":"2015","unstructured":"Gorchs L, Hellevik T, Bruun JA, Camilio KA, Al-Saad S, Stuge TB, Martinez-Zubiaurre I. Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation. Front Oncol. 2015;5:87.","journal-title":"Front Oncol"},{"issue":"2","key":"999_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00262-024-03889-x","volume":"74","author":"RA D\u2019Alonzo","year":"2025","unstructured":"D\u2019Alonzo RA, Keam S, Gill S, Rowshanfarzad P, Nowak AK, Ebert MA, Cook AM. Fractionated low-dose radiotherapy primes the tumor microenvironment for immunotherapy in a murine mesothelioma model. Cancer Immunol Immunother. 2025;74(2):44.","journal-title":"Cancer Immunol Immunother"},{"key":"999_CR7","doi-asserted-by":"crossref","unstructured":"Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, Cushman TR, Schoenhals JE, Cadena AP, Reilly TP et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020;8(2):e000537.","DOI":"10.1136\/jitc-2020-000537"},{"key":"999_CR8","doi-asserted-by":"crossref","unstructured":"Ochoa-de-Olza M, Rayroux N, Imbimbo M, Orcurto A, Fahr N, Benedetti F, Dagher J, Spagnol G, Barras D, Ghisoni E et al. Combinatorial delivery of low-dose radiotherapy and immunotherapy to patients with immune-excluded tumors enhances CD8+\u2009T cell functionality. Clin Cancer Res. 2026;32(14):2865\u201384.","DOI":"10.1158\/1078-0432.CCR-25-2743"},{"issue":"5","key":"999_CR9","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.21037\/tlcr-24-33","volume":"13","author":"L Wang","year":"2024","unstructured":"Wang L, Wu Y, Kang K, Zhang X, Luo R, Tu Z, Zheng Y, Lin G, Wang H, Tang M, et al. CDK4\/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer. Transl Lung Cancer Res. 2024;13(5):1032\u201346.","journal-title":"Transl Lung Cancer Res"},{"key":"999_CR10","doi-asserted-by":"publisher","first-page":"214463","DOI":"10.1016\/j.bioadv.2025.214463","volume":"178","author":"X Zhang","year":"2026","unstructured":"Zhang X, Li L, Niu H, Liang Z, Sang L, Wang N, Huang F, Han X, Liu Z, Shi X, et al. Evaluation of the anti-tumor effect of gambogic acid loaded macrophage membranes nanoparticles combined with radiotherapy and anti-PD-1mAb in the colorectal cancer with liver metastasis model. Biomater Adv. 2026;178:214463.","journal-title":"Biomater Adv"},{"issue":"1","key":"999_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12672-025-01794-y","volume":"16","author":"CQ Chen","year":"2025","unstructured":"Chen CQ, Huang H, Pan M, Jia Z, Zhang J, Chen QQ. Combination therapy of low-dose radiotherapy and immunotherapy in advanced metastatic nasopharyngeal carcinoma: a case report and literature review. Discov Oncol. 2025;16(1):52.","journal-title":"Discov Oncol"},{"issue":"1","key":"999_CR12","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1038\/s41467-025-59865-1","volume":"16","author":"Z Liu","year":"2025","unstructured":"Liu Z, Wang D, Li G, Yi M, Zhang Z, Zhong G, Xu L, Jiang R, Zheng Y, Huang L, et al. Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial. Nat Commun. 2025;16(1):4608.","journal-title":"Nat Commun"},{"issue":"10","key":"999_CR13","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.medj.2024.06.002","volume":"5","author":"H Wang","year":"2024","unstructured":"Wang H, Yao Z, Kang K, Zhou L, Xiu W, Sun J, Xie C, Yu M, Li Y, Zhang Y, et al. Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. Med. 2024;5(10):1237\u20131254.e9.","journal-title":"Med"},{"key":"999_CR14","doi-asserted-by":"publisher","first-page":"1503517","DOI":"10.3389\/fonc.2025.1503517","volume":"15","author":"Y Ding","year":"2025","unstructured":"Ding Y, Feng Y, Ye Y, Shen J, Guo C, He X, Zhu L, Wang L. High and low dose radiotherapy combined with ICIs for MSS colorectal cancer patients with liver metastases: a phase I study (HaRyPOT). Front Oncol. 2025;15:1503517.","journal-title":"Front Oncol"},{"key":"999_CR15","doi-asserted-by":"crossref","unstructured":"Liu B, Kong W, Zhang X, Ren B, Cheng Y, Su Y, Wang R, Feng Y, Zhou W. Targeting redox metabolism and low-dose radiotherapy synergistically activate cGAS-STING pathway to improve NK cell therapy efficacy in hepatocellular carcinoma. J Nanobiotechnol. 2026;24(1):295.","DOI":"10.1186\/s12951-026-04171-1"},{"key":"999_CR16","doi-asserted-by":"publisher","first-page":"110823","DOI":"10.1016\/j.radonc.2025.110823","volume":"206","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhang J, Liu Y, Jiang H, Wu B, Zhao S, Ouyang W, Hu Y, Lu B, Su S. Low-dose radiation as a potential strategy for alleviating lung injury caused by radiotherapy combined with immunotherapy: A preclinical study. Radiother Oncol. 2025;206:110823.","journal-title":"Radiother Oncol"},{"key":"999_CR17","doi-asserted-by":"publisher","first-page":"1663502","DOI":"10.3389\/fimmu.2025.1663502","volume":"16","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Su C, Pan J, Wang Y, Zhao M, Zhang M, Yan P, Liu N, Sun M. Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancer. Front Immunol. 2025;16:1663502.","journal-title":"Front Immunol"},{"key":"999_CR18","doi-asserted-by":"crossref","unstructured":"Li G, Yang X, Huang L, Zheng Y, Xu L, Zhang Z, Li J, Li T, Zhang Y, Yang Y et al. LDRT combined with anti-PD-1 promotes tumor regression in head and neck squamous cell carcinoma through tumor metaprogram evolution and immune cell reprogramming. J Exp Clin Cancer Res. 2026;45(1):68.","DOI":"10.1186\/s13046-026-03660-3"},{"issue":"11","key":"999_CR19","doi-asserted-by":"publisher","first-page":"17515","DOI":"10.1021\/acsnano.1c04363","volume":"15","author":"N Guo","year":"2021","unstructured":"Guo N, Ni K, Luo T, Lan G, Arina A, Xu Z, Mao J, Weichselbaum RR, Spiotto M, Lin W. Reprogramming of Neutrophils as Non-canonical Antigen Presenting Cells by Radiotherapy-Radiodynamic Therapy to Facilitate Immune-Mediated Tumor Regression. ACS Nano. 2021;15(11):17515\u201327.","journal-title":"ACS Nano"},{"issue":"11","key":"999_CR20","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11(11):1013.","journal-title":"Cell Death Dis"},{"key":"999_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3389\/fonc.2019.00811","volume":"9","author":"B Doix","year":"2019","unstructured":"Doix B, Trempolec N, Riant O, Feron O. Low Photosensitizer Dose and Early Radiotherapy Enhance Antitumor Immune Response of Photodynamic Therapy-Based Dendritic Cell Vaccination. Front Oncol. 2019;9:811.","journal-title":"Front Oncol"},{"key":"999_CR22","doi-asserted-by":"publisher","first-page":"1761538","DOI":"10.3389\/fimmu.2026.1761538","volume":"17","author":"M Li","year":"2026","unstructured":"Li M, Cui Z, Yang J, Sun Q, Hu Y, Shen J, Li Z, Han X, Wang Y, Tang J, et al. Iodine-125 brachytherapy triggers immunogenic cell death and potentiates anti-PD-L1 immunotherapy in bone metastatic triple-negative breast cancer. Front Immunol. 2026;17:1761538.","journal-title":"Front Immunol"},{"issue":"1","key":"999_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1748-717X-9-89","volume":"9","author":"Y Rubner","year":"2014","unstructured":"Rubner Y, Muth C, Strnad A, Derer A, Sieber R, Buslei R, Frey B, Fietkau R, Gaipl US. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Radiat Oncol. 2014;9(1):89.","journal-title":"Radiat Oncol"},{"issue":"1","key":"999_CR24","doi-asserted-by":"publisher","first-page":"e1523097","DOI":"10.1080\/2162402X.2018.1523097","volume":"8","author":"J Krombach","year":"2019","unstructured":"Krombach J, Hennel R, Brix N, Orth M, Schoetz U, Ernst A, Schuster J, Zuchtriegel G, Reichel CA, Bierschenk S, et al. Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells. Oncoimmunology. 2019;8(1):e1523097.","journal-title":"Oncoimmunology"},{"issue":"33","key":"999_CR25","doi-asserted-by":"publisher","first-page":"46705","DOI":"10.1021\/acsami.5c10385","volume":"17","author":"J Yang","year":"2025","unstructured":"Yang J, Cao H, Tang H, Yin Z, Li P, Liu J, Yang C, Zhang W. Ex Vivo High-Dose Ionizing Irradiation-Conditioned Nanovesicles for Enhancing the Immune Effects of Tumor Radiotherapy. ACS Appl Mater Interfaces. 2025;17(33):46705\u201319.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"999_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12951-025-03281-6","volume":"23","author":"W Zhuang","year":"2025","unstructured":"Zhuang W, Pan K, Wu J, Liu L, Lv S, Hu J, Shi F, Zhao W, Yu D. Harnessing the power of traceable system C-GAP: homologous-targeting to fire up T-cell immune responses with low-dose irradiation. J Nanobiotechnol. 2025;23(1):207.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"999_CR27","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1186\/s12951-024-02999-z","volume":"22","author":"M Xu","year":"2024","unstructured":"Xu M, Xu C, Qiu Y, Feng Y, Shi Q, Liu Y, Deng H, Ma X, Lin N, Shi Q, et al. Zinc-based radioenhancers to activate tumor radioimmunotherapy by PD-L1 and cGAS-STING pathway. J Nanobiotechnol. 2024;22(1):782.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"999_CR28","doi-asserted-by":"publisher","first-page":"8845","DOI":"10.1038\/s41467-024-53015-9","volume":"15","author":"P Bergeron","year":"2024","unstructured":"Bergeron P, Dos Santos M, Sitterle L, Tarlet G, Lavigne J, Liu W, Gerb\u00e9 de Thor\u00e9 M, Cl\u00e9menson C, Meziani L, Schott C, et al. Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade. Nat Commun. 2024;15(1):8845.","journal-title":"Nat Commun"},{"issue":"4","key":"999_CR29","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.apsb.2023.11.028","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang L, Li T, Ouyang M, Xiong H, Zhou D. Bimetallic nanoparticles as cascade sensitizing amplifiers for low-dose and robust cancer radio-immunotherapy. Acta Pharm Sin B. 2024;14(4):1787\u2013800.","journal-title":"Acta Pharm Sin B"},{"key":"999_CR30","doi-asserted-by":"publisher","first-page":"14551","DOI":"10.2147\/IJN.S563439","volume":"20","author":"Y Chen","year":"2025","unstructured":"Chen Y, Wang J, Zheng D, Zhang W. Tumor Microenvironment Reprogramming via Copper-Enriched Black Phosphorus Nanoplatform for Cuproptosis-Sensitized Low-Dose Radioimmunotherapy. Int J Nanomed. 2025;20:14551\u201369.","journal-title":"Int J Nanomed"},{"issue":"9","key":"999_CR31","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050\u20139.","journal-title":"Nat Med"},{"key":"999_CR32","doi-asserted-by":"crossref","unstructured":"Li Y, Ni K, Chan C, Guo N, Luo T, Han W, Culbert A, Weichselbaum RR, Lin W. Dimethylaminomicheliolide sensitizes cancer cells to radiotherapy for synergistic combination with immune checkpoint blockade. Adv Ther (Weinh). 2022;5(1):2100160.","DOI":"10.1002\/adtp.202100160"},{"issue":"4","key":"999_CR33","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.7150\/thno.124034","volume":"16","author":"B Zeng","year":"2026","unstructured":"Zeng B, Ling K, Yuan Q, Chen Z, Zhang G, Kang W, Zheng X, Liao C, Mai Y, Huang Z, et al. An organolutetium nanosensitizer synergizes with PARP inhibition to unleash STING-mediated immunity for low-dose radioimmunotherapy. Theranostics. 2026;16(4):1720\u201339.","journal-title":"Theranostics"},{"key":"999_CR34","doi-asserted-by":"crossref","unstructured":"Laurent PA, Shi L, Bouarroudj L, Benzazon N, Gerb\u00e9 De Thor\u00e9 M, Liu W, Aglave M, Bergeron P, Naulin F, Sitterl\u00e9 L et al. Low-dose radiotherapy enhances the efficacy of PD-L1 blockade and induces the abscopal effect. J Immunother Cancer. 2025;13(6):e011487.","DOI":"10.1136\/jitc-2025-011487"},{"key":"999_CR35","doi-asserted-by":"publisher","first-page":"112768","DOI":"10.1016\/j.intimp.2024.112768","volume":"140","author":"M He","year":"2024","unstructured":"He M, Jiang H, Li S, Xue M, Wang H, Zheng C, Tong J. The crosstalk between DNA-damage responses and innate immunity. Int Immunopharmacol. 2024;140:112768.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"999_CR36","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014;41(5):843\u201352.","journal-title":"Immunity"},{"issue":"3","key":"999_CR37","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.celrep.2014.01.003","volume":"6","author":"X Zhang","year":"2014","unstructured":"Zhang X, Wu J, Du F, Xu H, Sun L, Chen Z, Brautigam CA, Zhang X, Chen ZJ. The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch-like conformational changes in the activation loop. Cell Rep. 2014;6(3):421\u201330.","journal-title":"Cell Rep"},{"key":"999_CR38","doi-asserted-by":"publisher","first-page":"646304","DOI":"10.3389\/fimmu.2021.646304","volume":"12","author":"T Taguchi","year":"2021","unstructured":"Taguchi T, Mukai K, Takaya E, Shindo R. STING Operation at the ER\/Golgi Interface. Front Immunol. 2021;12:646304.","journal-title":"Front Immunol"},{"issue":"1","key":"999_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF. The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer. Cancer Discov. 2020;10(1):26\u201339.","journal-title":"Cancer Discov"},{"key":"999_CR40","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.","journal-title":"Nat Commun"},{"issue":"2","key":"999_CR41","doi-asserted-by":"publisher","first-page":"e6950","DOI":"10.1002\/cam4.6950","volume":"13","author":"W Hu","year":"2024","unstructured":"Hu W, Zhang Z, Xue Y, Ning R, Guo X, Sun Y, Zhang Q. Carbon ion irradiation exerts antitumor activity by inducing cGAS-STING activation and immune response in prostate cancer-bearing mice. Cancer Med. 2024;13(2):e6950.","journal-title":"Cancer Med"},{"key":"999_CR42","doi-asserted-by":"publisher","first-page":"218132","DOI":"10.1016\/j.canlet.2025.218132","volume":"637","author":"YY Tsai","year":"2026","unstructured":"Tsai YY, Chang HY, Hong WZ, Chen JY, Chiang SF, Lin YS, Ke TW, Huang CH, Chen TH, Jiang YW, et al. Targeting DRP1 promotes radiotherapy-induced antitumor immunity via mitochondrial DNA-mediated cGAS-STING signaling in KRAS-mutated colorectal cancer. Cancer Lett. 2026;637:218132.","journal-title":"Cancer Lett"},{"issue":"1","key":"999_CR43","doi-asserted-by":"publisher","first-page":"11622","DOI":"10.1038\/s41467-025-66630-x","volume":"16","author":"P Sun","year":"2025","unstructured":"Sun P, Han F, Li X, Wu C, Deng T, He J, Zhang C, Kuai R. Silencing PCSK9 reshapes the spatiotemporal activation of STING for safe and effective cancer immunotherapy. Nat Commun. 2025;16(1):11622.","journal-title":"Nat Commun"},{"issue":"20","key":"999_CR44","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1016\/j.molcel.2025.08.030","volume":"85","author":"A Shim","year":"2025","unstructured":"Shim A, Chen Y, Maciejowski J. Activation and regulation of cGAS-STING signaling in cancer cells. Mol Cell. 2025;85(20):3807\u201322.","journal-title":"Mol Cell"},{"issue":"1","key":"999_CR45","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41420-022-01256-2","volume":"8","author":"D Han","year":"2022","unstructured":"Han D, Zhang J, Bao Y, Liu L, Wang P, Qian D. Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS\/STING in non-small cell lung cancer. Cell Death Discov. 2022;8(1):468.","journal-title":"Cell Death Discov"},{"issue":"29","key":"999_CR46","doi-asserted-by":"publisher","first-page":"e2302220","DOI":"10.1002\/adma.202302220","volume":"35","author":"N Liu","year":"2023","unstructured":"Liu N, Zhu J, Zhu W, Chen L, Li M, Shen J, Chen M, Wu Y, Pan F, Deng Z, et al. X-ray-Induced Release of Nitric Oxide from Hafnium-Based Nanoradiosensitizers for Enhanced Radio-Immunotherapy. Adv Mater. 2023;35(29):e2302220.","journal-title":"Adv Mater"},{"issue":"801","key":"999_CR47","doi-asserted-by":"publisher","first-page":"eadn6921","DOI":"10.1126\/scitranslmed.adn6921","volume":"17","author":"R Yang","year":"2025","unstructured":"Yang R, Wang B, Su Z, Song Y, Zhang Y, Liu Y, Zhang Y, He C, Yang X, Zhong F, et al. Methotrexate exerts antitumor immune activity and improves the clinical efficacy of immunotherapy in patients with solid tumors. Sci Transl Med. 2025;17(801):eadn6921.","journal-title":"Sci Transl Med"},{"key":"999_CR48","doi-asserted-by":"publisher","first-page":"115557","DOI":"10.1016\/j.biopha.2023.115557","volume":"167","author":"A Najafi","year":"2023","unstructured":"Najafi A, Keykhaee M, Kazemi MH, Karimi MY, Khorramdelazad H, Aghamohamadi N, Bolouri MR, Ghaffari-Nazari H, Mirsharif ES, Karimi M, et al. Catalase-gold nanoaggregates manipulate the tumor microenvironment and enhance the effect of low-dose radiation therapy by reducing hypoxia. Biomed Pharmacother. 2023;167:115557.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"999_CR49","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et al. Low-dose irradiation programs macrophage differentiation to an iNOS\u207a\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24(5):589\u2013602.","journal-title":"Cancer Cell"},{"issue":"1","key":"999_CR50","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s12672-025-03258-9","volume":"16","author":"M Peng","year":"2025","unstructured":"Peng M, Zhu Y, Hu Y, Wen J, Huang W. Advances in the regulation of macrophage polarization by the tumor microenvironment. Discov Oncol. 2025;16(1):1487.","journal-title":"Discov Oncol"},{"issue":"1","key":"999_CR51","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.1038\/s41467-025-60769-3","volume":"16","author":"X Yin","year":"2025","unstructured":"Yin X, Ding Z, Yu L, Zhang X, Gao Y, Li Y, Liu Z, Fu YX. Orchestrating intratumoral DC-T cell immunity for enhanced tumor control via radiotherapy-activated TLR7\/8 prodrugs in mice. Nat Commun. 2025;16(1):6020.","journal-title":"Nat Commun"},{"issue":"1","key":"999_CR52","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, et al. Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discov. 2022;12(1):108\u201333.","journal-title":"Cancer Discov"},{"issue":"2","key":"999_CR53","doi-asserted-by":"publisher","first-page":"718","DOI":"10.4103\/jcrt.jcrt_616_23","volume":"20","author":"X Luo","year":"2024","unstructured":"Luo X, Zeng M. Combination low-dose cyclophosphamide with check-point blockade and ionizing radiation promote an abscopal effect in mouse models of melanoma. J Cancer Res Ther. 2024;20(2):718\u201325.","journal-title":"J Cancer Res Ther"},{"issue":"14","key":"999_CR54","doi-asserted-by":"publisher","first-page":"13333","DOI":"10.1021\/acsnano.3c01428","volume":"17","author":"J Kuang","year":"2023","unstructured":"Kuang J, Rao ZY, Zheng DW, Kuang D, Huang QX, Pan T, Li H, Zeng X, Zhang XZ. Nanoparticles Hitchhike on Monocytes for Glioblastoma Treatment after Low-Dose Radiotherapy. ACS Nano. 2023;17(14):13333\u201347.","journal-title":"ACS Nano"},{"issue":"1","key":"999_CR55","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12967-024-05118-6","volume":"22","author":"H Yang","year":"2024","unstructured":"Yang H, Lei Z, He J, Zhang L, Lai T, Zhou L, Wang N, Tang Z, Sui J, Wu Y. Single-cell RNA sequencing reveals recruitment of the M2-like CCL8(high) macrophages in Lewis lung carcinoma-bearing mice following hypofractionated radiotherapy. J Transl Med. 2024;22(1):306.","journal-title":"J Transl Med"},{"issue":"8","key":"999_CR56","doi-asserted-by":"publisher","first-page":"e69182","DOI":"10.1371\/journal.pone.0069182","volume":"8","author":"SC Wang","year":"2013","unstructured":"Wang SC, Yu CF, Hong JH, Tsai CS, Chiang CS. Radiation therapy-induced tumor invasiveness is associated with SDF-1-regulated macrophage mobilization and vasculogenesis. PLoS ONE. 2013;8(8):e69182.","journal-title":"PLoS ONE"},{"issue":"45","key":"999_CR57","doi-asserted-by":"publisher","first-page":"53504","DOI":"10.1021\/acsami.1c07626","volume":"13","author":"Y Cao","year":"2021","unstructured":"Cao Y, Ding S, Zeng L, Miao J, Wang K, Chen G, Li C, Zhou J, Bian XW, Tian G. Reeducating Tumor-Associated Macrophages Using CpG@Au Nanocomposites to Modulate Immunosuppressive Microenvironment for Improved Radio-Immunotherapy. ACS Appl Mater Interfaces. 2021;13(45):53504\u201318.","journal-title":"ACS Appl Mater Interfaces"},{"key":"999_CR58","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.jconrel.2024.06.062","volume":"372","author":"BN Dang","year":"2024","unstructured":"Dang BN, Duwa R, Lee S, Kwon TK, Chang JH, Jeong JH, Yook S. Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7\/8 agonist enhances cancer immunotherapy. J Control Release. 2024;372:587\u2013608.","journal-title":"J Control Release"},{"issue":"6","key":"999_CR59","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/ijc.34364","volume":"152","author":"J Hey","year":"2023","unstructured":"Hey J, Halperin C, Hartmann M, Mayer S, Sch\u00f6nung M, Lipka DB, Scherz-Shouval R, Plass C. DNA methylation landscape of tumor-associated macrophages reveals pathways, transcription factors and prognostic value relevant to triple-negative breast cancer patients. Int J Cancer. 2023;152(6):1226\u201342.","journal-title":"Int J Cancer"},{"key":"999_CR60","doi-asserted-by":"publisher","first-page":"1521550","DOI":"10.3389\/fimmu.2025.1521550","volume":"16","author":"Y Xu","year":"2025","unstructured":"Xu Y, Zhang H, Nie D. Histone modifications and metabolic reprogramming in tumor-associated macrophages: a potential target of tumor immunotherapy. Front Immunol. 2025;16:1521550.","journal-title":"Front Immunol"},{"issue":"1","key":"999_CR61","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1038\/s41467-021-23086-z","volume":"12","author":"S Shinde-Jadhav","year":"2021","unstructured":"Shinde-Jadhav S, Mansure JJ, Rayes RF, Marcq G, Ayoub M, Skowronski R, Kool R, Bourdeau F, Brimo F, Spicer J, et al. Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer. Nat Commun. 2021;12(1):2776.","journal-title":"Nat Commun"},{"issue":"18","key":"999_CR62","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1158\/1078-0432.CCR-23-3860","volume":"30","author":"A Teijeira","year":"2024","unstructured":"Teijeira A, Garasa S, Ochoa MC, Sanchez-Gregorio S, Gomis G, Luri-Rey C, Martinez-Monge R, Pinci B, Valencia K, Palencia B, et al. Low-Dose Ionizing \u03b3-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps. Clin Cancer Res. 2024;30(18):4131\u201342.","journal-title":"Clin Cancer Res"},{"key":"999_CR63","doi-asserted-by":"publisher","first-page":"1169670","DOI":"10.3389\/fimmu.2023.1169670","volume":"14","author":"J Hu","year":"2023","unstructured":"Hu J, Pan M, Wang Y, Zhu Y, Wang M. Functional plasticity of neutrophils after low- or high-dose irradiation in cancer treatment - A mini review. Front Immunol. 2023;14:1169670.","journal-title":"Front Immunol"},{"issue":"3","key":"999_CR64","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.21037\/tlcr-21-152","volume":"10","author":"Q Liu","year":"2021","unstructured":"Liu Q, Hao Y, Du R, Hu D, Xie J, Zhang J, Deng G, Liang N, Tian T, K\u00e4smann L, et al. Radiotherapy programs neutrophils to an antitumor phenotype by inducing mesenchymal-epithelial transition. Transl Lung Cancer Res. 2021;10(3):1424\u201343.","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"999_CR65","doi-asserted-by":"publisher","first-page":"189538","DOI":"10.1016\/j.bbcan.2026.189538","volume":"1881","author":"W Bi","year":"2026","unstructured":"Bi W, Li X, Zhao H, Han Q, Zhang J. Heterogeneous neutrophils: Key players in regulating tumor immunity. Biochim Biophys Acta Rev Cancer. 2026;1881(2):189538.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"4","key":"999_CR66","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41419-018-0458-4","volume":"9","author":"Y Cheng","year":"2018","unstructured":"Cheng Y, Li H, Deng Y, Tai Y, Zeng K, Zhang Y, Liu W, Zhang Q, Yang Y. Cancer-associated fibroblasts induce PDL1\u2009+\u2009neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. Cell Death Dis. 2018;9(4):422.","journal-title":"Cell Death Dis"},{"issue":"2","key":"999_CR67","doi-asserted-by":"publisher","first-page":"e70063","DOI":"10.1002\/mco2.70063","volume":"6","author":"W He","year":"2025","unstructured":"He W, Yan L, Hu D, Hao J, Liou YC, Luo G. Neutrophil heterogeneity and plasticity: unveiling the multifaceted roles in health and disease. MedComm (2020). 2025;6(2):e70063.","journal-title":"MedComm (2020)"},{"key":"999_CR68","doi-asserted-by":"crossref","unstructured":"Garratt LW. Current understanding of the neutrophil transcriptome in health and disease. Cells. 2021;10(9):2406.","DOI":"10.3390\/cells10092406"},{"key":"999_CR69","doi-asserted-by":"crossref","unstructured":"Xu H, Chen X, Lu Y, Sun N, Weisgerber KE, Xu M, Bai RY. Neutrophil dynamics in response to cancer therapies. Cancers (Basel). 2025;17(15):2593.","DOI":"10.3390\/cancers17152593"},{"issue":"1","key":"999_CR70","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijrobp.2021.04.009","volume":"111","author":"E Reijmen","year":"2021","unstructured":"Reijmen E, De Mey S, De Mey W, Gevaert T, De Ridder K, Locy H, Martens S, De Blay E, Bouwens L, Debie P, et al. Fractionated Radiation Severely Reduces the Number of CD8+\u2009T Cells and Mature Antigen Presenting Cells Within Lung Tumors. Int J Radiat Oncol Biol Phys. 2021;111(1):272\u201383.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"999_CR71","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/08916934.2017.1284819","volume":"50","author":"PF R\u00fchle","year":"2017","unstructured":"R\u00fchle PF, Wunderlich R, Deloch L, Fournier C, Maier A, Klein G, Fietkau R, Gaipl US, Frey B. Modulation of the peripheral immune system after low-dose radon spa therapy: Detailed longitudinal immune monitoring of patients within the RAD-ON01 study. Autoimmunity. 2017;50(2):133\u201340.","journal-title":"Autoimmunity"},{"issue":"2","key":"999_CR72","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41551-022-00846-w","volume":"6","author":"K Ni","year":"2022","unstructured":"Ni K, Xu Z, Culbert A, Luo T, Guo N, Yang K, Pearson E, Preusser B, Wu T, La Riviere P, et al. Synergistic checkpoint-blockade and radiotherapy-radiodynamic therapy via an immunomodulatory nanoscale metal-organic framework. Nat Biomed Eng. 2022;6(2):144\u201356.","journal-title":"Nat Biomed Eng"},{"key":"999_CR73","doi-asserted-by":"crossref","unstructured":"Heiserman JP, Akhurst RJ. Diverse biological processes contribute to transforming growth factor \u03b2-mediated cancer drug resistance. Cells. 2025;14(19):1518.","DOI":"10.3390\/cells14191518"},{"issue":"8","key":"999_CR74","doi-asserted-by":"publisher","first-page":"110562","DOI":"10.1016\/j.isci.2024.110562","volume":"27","author":"KH Tsui","year":"2024","unstructured":"Tsui KH, Liu CL, Yeh HL, Liu MK, Li CH, Chen WH, Jiang KC, Li HR, Thuy Dung PV, Hsiao M, et al. WNT1-inducible signaling pathway protein 1 activation through C-X-C motif chemokine ligand 5\/C-X-C chemokine receptor type 2\/leukemia inhibitory factor\/leukemia inhibitory factor receptor signaling promotes immunosuppression and neuroendocrine differentiation in prostate cancer. iScience. 2024;27(8):110562.","journal-title":"iScience"},{"key":"999_CR75","doi-asserted-by":"crossref","unstructured":"Kroemer G, Zitvogel L. Immune checkpoint inhibitors. J Exp Med. 2021;218(3):e20201979.","DOI":"10.1084\/jem.20201979"},{"issue":"5256","key":"999_CR76","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734\u20136.","journal-title":"Science"},{"issue":"19","key":"999_CR77","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"999_CR78","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"999_CR79","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"999_CR80","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","volume":"23","author":"HE Marei","year":"2023","unstructured":"Marei HE, Hasan A, Pozzoli G, Cenciarelli C. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int. 2023;23(1):64.","journal-title":"Cancer Cell Int"},{"issue":"11","key":"999_CR81","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.21037\/tlcr-2025-921","volume":"14","author":"Y Han","year":"2025","unstructured":"Han Y, Wang J, Pang B, Zhang J, Zhao X, Hao S, Zhang Q, Ren X, Sun L. Immune checkpoint inhibitors have limited efficacy in SMARCA4-deficient non-small cell lung cancer. Transl Lung Cancer Res. 2025;14(11):5000\u201316.","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"999_CR82","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/oncolo\/oyac040","volume":"27","author":"J Gantzer","year":"2022","unstructured":"Gantzer J, Davidson G, Vokshi B, Weingertner N, Bougo\u00fcin A, Moreira M, Lindner V, Lacroix G, Mascaux C, Chenard MP, et al. Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors. Oncologist. 2022;27(6):501\u201311.","journal-title":"Oncologist"},{"issue":"7854","key":"999_CR83","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450\u20136.","journal-title":"Nature"},{"key":"999_CR84","doi-asserted-by":"crossref","unstructured":"Drewniak-\u015awitalska M, Fortuna P, Krzystek-Korpacka M. Negative immune checkpoint inhibitors. Pharmaceutics. 2025;17(6):713.","DOI":"10.3390\/pharmaceutics17060713"},{"key":"999_CR85","doi-asserted-by":"crossref","unstructured":"Naidoo J, Cottrell TR, Lipson EJ, Forde PM, Illei PB, Yarmus LB, Voong KR, Feller-Kopman D, Lee H, Riemer J et al. Chronic immune checkpoint inhibitor pneumonitis. J Immunother Cancer. 2020;8(1):e000840.","DOI":"10.1136\/jitc-2020-000840"},{"issue":"7","key":"999_CR86","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","volume":"23","author":"RP Patel","year":"2021","unstructured":"Patel RP, Parikh R, Gunturu KS, Tariq RZ, Dani SS, Ganatra S, Nohria A. Cardiotoxicity of Immune Checkpoint Inhibitors. Curr Oncol Rep. 2021;23(7):79.","journal-title":"Curr Oncol Rep"},{"issue":"18","key":"999_CR87","doi-asserted-by":"publisher","first-page":"e38023","DOI":"10.1016\/j.heliyon.2024.e38023","volume":"10","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Akin S. Immune checkpoint blockade and CAR T-cell therapy in T-cell\/histiocyte-rich large B-cell lymphoma: Challenges and opportunities. Heliyon. 2024;10(18):e38023.","journal-title":"Heliyon"},{"key":"999_CR88","doi-asserted-by":"crossref","unstructured":"Zhao X, Wangmo D, Robertson M, Subramanian S. Acquired resistance to immune checkpoint blockade therapies. Cancers (Basel). 2020;12(5):1161.","DOI":"10.3390\/cancers12051161"},{"key":"999_CR89","doi-asserted-by":"publisher","first-page":"118014","DOI":"10.1016\/j.biopha.2025.118014","volume":"186","author":"A Rahimi","year":"2025","unstructured":"Rahimi A, Baghernejadan Z, Hazrati A, Malekpour K, Samimi LN, Najafi A, Falak R, Khorramdelazad H. Combination therapy with immune checkpoint inhibitors in colorectal cancer: Challenges, resistance mechanisms, and the role of microbiota. Biomed Pharmacother. 2025;186:118014.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"999_CR90","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"},{"issue":"1","key":"999_CR91","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12902-022-01017-3","volume":"22","author":"F Xu","year":"2022","unstructured":"Xu F, Guan Y, Zhang P, Xue L, Ma Y, Gao M, Chong T, Ren BC. Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma. BMC Endocr Disord. 2022;22(1):130.","journal-title":"BMC Endocr Disord"},{"issue":"15","key":"999_CR92","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.2169\/internalmedicine.6798-20","volume":"60","author":"T Asoh","year":"2021","unstructured":"Asoh T, Yanagihara T, Tanaka R, Yoneda R. Tracheobronchial Chondritis Associated with Immune Checkpoint Blockade. Intern Med. 2021;60(15):2517\u20138.","journal-title":"Intern Med"},{"issue":"6371","key":"999_CR93","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science"},{"key":"999_CR94","doi-asserted-by":"publisher","unstructured":"Zhou J, Zeng X, Sun J, Yang Y, Wang J, Xiao X, et al. Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efficacy inesophageal squamous cell carcinoma. Cell Host Microbe. 2026;34(4):639\u201356.e10. https:\/\/doi.org\/10.1016\/j.chom.2026.02.019","DOI":"10.1016\/j.chom.2026.02.019"},{"issue":"8","key":"999_CR95","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","volume":"25","author":"C Lynch","year":"2024","unstructured":"Lynch C, Pitroda SP, Weichselbaum RR. Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 2024;25(8):e352\u201362.","journal-title":"Lancet Oncol"},{"key":"999_CR96","doi-asserted-by":"publisher","first-page":"963533","DOI":"10.3389\/fimmu.2022.963533","volume":"13","author":"X Qian","year":"2022","unstructured":"Qian X, Hu W, Yan J. Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option? Front Immunol. 2022;13:963533.","journal-title":"Front Immunol"},{"issue":"42","key":"999_CR97","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.3748\/wjg.v28.i42.6034","volume":"28","author":"SQ Li","year":"2022","unstructured":"Li SQ, Yang Y, Ye LS. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. World J Gastroenterol. 2022;28(42):6034\u201344.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"999_CR98","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","volume":"10","author":"W Xiao","year":"2025","unstructured":"Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W, Hu Y, Shi J. Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target Ther. 2025;10(1):74.","journal-title":"Signal Transduct Target Ther"},{"key":"999_CR99","doi-asserted-by":"crossref","unstructured":"Healey Bird B, Nally K, Ronan K, Clarke G, Amu S, Almeida AS, Flavin R, Finn S. Cancer immunotherapy with immune checkpoint inhibitors-biomarkers of response and toxicity; current limitations and future promise. Diagnostics (Basel). 2022;12(1):124.","DOI":"10.3390\/diagnostics12010124"},{"issue":"12","key":"999_CR100","doi-asserted-by":"publisher","first-page":"e70113","DOI":"10.1111\/1759-7714.70113","volume":"16","author":"X Pu","year":"2025","unstructured":"Pu X, Zhou Y, Wang J, Wu L. Immune Checkpoint Inhibitor-Based Therapy as the First-Line Treatment for Advanced Non-Small Cell Lung Cancer: Efficacy, Challenges, and Future Perspectives. Thorac Cancer. 2025;16(12):e70113.","journal-title":"Thorac Cancer"},{"issue":"8","key":"999_CR101","doi-asserted-by":"publisher","first-page":"e094859","DOI":"10.1136\/bmjopen-2024-094859","volume":"15","author":"R Zhang","year":"2025","unstructured":"Zhang R, Chen M, Yin N, Xue J. Low-dose radiation and stereotactic body radiotherapy with PD-1 inhibitor sintilimab and chemotherapy for first-line treatment of locally advanced or metastatic squamous lung cancer: protocol for a randomised phase II trial (IHC002 study). BMJ Open. 2025;15(8):e094859.","journal-title":"BMJ Open"},{"key":"999_CR102","doi-asserted-by":"publisher","first-page":"1618110","DOI":"10.3389\/fimmu.2025.1618110","volume":"16","author":"J Chen","year":"2025","unstructured":"Chen J, Wang J, Fang W, Wu Y, Li H, Xu H, Zhu Y, Cheng Y, Yu Z, Peng Y. BRICS sequential therapeutic regimen as first-Line treatment for PD-L1-negative metastatic non-small cell lung cancer patients harboring EGFR\/ALK wild-type status: a retrospective study. Front Immunol. 2025;16:1618110.","journal-title":"Front Immunol"},{"issue":"3","key":"999_CR103","doi-asserted-by":"publisher","first-page":"33","DOI":"10.21037\/cco-24-115","volume":"14","author":"E Atak","year":"2025","unstructured":"Atak E, Kutuk T, La Rosa A, Mehta MP, Gutierrez AN, Kotecha R. Pulsed reduced dose rate radiotherapy: a narrative review. Chin Clin Oncol. 2025;14(3):33.","journal-title":"Chin Clin Oncol"},{"key":"999_CR104","doi-asserted-by":"publisher","first-page":"1554018","DOI":"10.3389\/fimmu.2025.1554018","volume":"16","author":"X Zeng","year":"2025","unstructured":"Zeng X, Jin X, Leng J, Zhang S, Wang Y, Chen J, Zhang S, Teng L, Hu Z, Zhou S, et al. High-dose radiation induces dendritic cells maturation by promoting immunogenic cell death in nasopharyngeal carcinoma. Front Immunol. 2025;16:1554018.","journal-title":"Front Immunol"},{"issue":"2","key":"999_CR105","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41590-019-0561-4","volume":"21","author":"ME Rodriguez-Ruiz","year":"2020","unstructured":"Rodriguez-Ruiz ME, Vitale I, Harrington KJ, Melero I, Galluzzi L. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nat Immunol. 2020;21(2):120\u201334.","journal-title":"Nat Immunol"},{"issue":"1","key":"999_CR106","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","volume":"8","author":"S Guo","year":"2023","unstructured":"Guo S, Yao Y, Tang Y, Xin Z, Wu D, Ni C, Huang J, Wei Q, Zhang T. Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal Transduct Target Ther. 2023;8(1):205.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"999_CR107","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ijrobp.2022.06.054","volume":"114","author":"Y Chiang","year":"2022","unstructured":"Chiang Y, Tsai YC, Wang CC, Hsueh FJ, Huang CY, Chung SD, Chen CH, Pu YS, Cheng JC. Tumor-Derived C-C Motif Ligand 2 Induces the Recruitment and Polarization of Tumor-Associated Macrophages and Increases the Metastatic Potential of Bladder Cancer Cells in the Postirradiated Microenvironment. Int J Radiat Oncol Biol Phys. 2022;114(2):321\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"999_CR108","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijrobp.2020.08.037","volume":"109","author":"J Brooks","year":"2021","unstructured":"Brooks J, Kumar B, Zuro DM, Raybuck JD, Madabushi SS, Vishwasrao P, Parra LE, Kortylewski M, Armstrong B, Froelich J, et al. Biophysical Characterization of the Leukemic Bone Marrow Vasculature Reveals Benefits of Neoadjuvant Low-Dose Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021;109(1):60\u201372.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"999_CR109","doi-asserted-by":"publisher","first-page":"1106644","DOI":"10.3389\/fimmu.2022.1106644","volume":"13","author":"X Ji","year":"2022","unstructured":"Ji X, Jiang W, Wang J, Zhou B, Ding W, Liu S, Huang H, Chen G, Sun X. Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. Front Immunol. 2022;13:1106644.","journal-title":"Front Immunol"},{"key":"999_CR110","doi-asserted-by":"publisher","first-page":"1558814","DOI":"10.3389\/fimmu.2025.1558814","volume":"16","author":"J Luo","year":"2025","unstructured":"Luo J, Zhi Q, Li D, Xu Y, Zhu H, Zhao L, Ren G, Wang J, Liu N. Low dose radiotherapy combined with immune checkpoint inhibitors induces ferroptosis in lung cancer via the Nrf2\/HO-1\/GPX4 axis. Front Immunol. 2025;16:1558814.","journal-title":"Front Immunol"},{"issue":"1","key":"999_CR111","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.1038\/s41598-021-84872-9","volume":"11","author":"G Jacobson","year":"2021","unstructured":"Jacobson G, Kaidar-Person O, Haisraely O, Galper S, Rabin T, Dromi Shahadi I, Lawrence YR, Symon Z, Akiva Ben-David M. Palliative radiation therapy for symptomatic advance breast cancer. Sci Rep. 2021;11(1):5282.","journal-title":"Sci Rep"},{"issue":"4","key":"999_CR112","doi-asserted-by":"publisher","first-page":"403","DOI":"10.21873\/cdp.10232","volume":"3","author":"IM Koukourakis","year":"2023","unstructured":"Koukourakis IM, Xanthopoulou E, Koukourakis MI. Using Liquid Biopsy to Predict Relapse After Radiotherapy in Squamous Cell Head-Neck and Esophageal Cancer. Cancer Diagn Progn. 2023;3(4):403\u201310.","journal-title":"Cancer Diagn Progn"},{"issue":"14","key":"999_CR113","doi-asserted-by":"publisher","first-page":"e71065","DOI":"10.1002\/cam4.71065","volume":"14","author":"W Li","year":"2025","unstructured":"Li W, Xu M, Cheng M, Wei J, Zhu L, Deng Y, Guo F, Bi F, Liu M. Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors. Cancer Med. 2025;14(14):e71065.","journal-title":"Cancer Med"},{"key":"999_CR114","doi-asserted-by":"crossref","unstructured":"Spiotto M, Fu YX, Weichselbaum RR. The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci Immunol. 2016;1(3):eaag1266.","DOI":"10.1126\/sciimmunol.aag1266"},{"issue":"1","key":"999_CR115","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13014-025-02596-w","volume":"20","author":"J Fu","year":"2025","unstructured":"Fu J, Liu X, Zhou Y, Zhao S, Zeng L, Pan Y, Zhang J, Prise KM, Shao C, Xu Y. Development of delayed pulmonary toxicities and transcriptional changes in pre-existing interstitial lung disease mice after partial thoracic irradiation. Radiat Oncol. 2025;20(1):20.","journal-title":"Radiat Oncol"},{"issue":"3","key":"999_CR116","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/jamaoncol.2024.5780","volume":"11","author":"I Meattini","year":"2025","unstructured":"Meattini I, Coles CE, Tramm T, Borghesi S, Krug D, Montero A, Nardone V, Salvestrini V, Valzano M, Valentini V, et al. Biomarker-Directed Radiotherapy in Breast Cancer: A Narrative Review. JAMA Oncol. 2025;11(3):329\u201339.","journal-title":"JAMA Oncol"},{"key":"999_CR117","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3389\/fonc.2020.00628","volume":"10","author":"J Meehan","year":"2020","unstructured":"Meehan J, Gray M, Mart\u00ednez-P\u00e9rez C, Kay C, Pang LY, Fraser JA, Poole AV, Kunkler IH, Langdon SP, Argyle D, et al. Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer. Front Oncol. 2020;10:628.","journal-title":"Front Oncol"},{"issue":"2","key":"999_CR118","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1470-2045(16)30648-9","volume":"18","author":"JG Scott","year":"2017","unstructured":"Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. 2017;18(2):202\u201311.","journal-title":"Lancet Oncol"},{"issue":"19","key":"999_CR119","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1158\/1078-0432.CCR-18-0825","volume":"24","author":"Y Cui","year":"2018","unstructured":"Cui Y, Li B, Pollom EL, Horst KC, Li R. Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer. Clin Cancer Res. 2018;24(19):4754\u201362.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"999_CR120","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ijc.35152","volume":"156","author":"F Janke","year":"2025","unstructured":"Janke F, Stritzke F, Dvornikovich K, Franke H, Angeles AK, Riediger AL, Ogrodnik S, Gerhardt S, Regnery S, Schr\u00f6ter P, et al. Early circulating tumor DNA changes predict outcomes in head and neck cancer patients under re-radiotherapy. Int J Cancer. 2025;156(4):853\u201364.","journal-title":"Int J Cancer"},{"key":"999_CR121","doi-asserted-by":"publisher","first-page":"100626","DOI":"10.1016\/j.phro.2024.100626","volume":"31","author":"Y Zha","year":"2024","unstructured":"Zha Y, Ye Z, Zapaishchykova A, He J, Hsu SH, Leeman JE, Fitzgerald KJ, Kozono DE, Mak RH, Aerts HJWL, et al. Delta radiomics to track radiation response in lung tumors receiving stereotactic magnetic resonance-guided radiotherapy. Phys Imaging Radiat Oncol. 2024;31:100626.","journal-title":"Phys Imaging Radiat Oncol"},{"issue":"1","key":"999_CR122","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13014-025-02738-0","volume":"20","author":"J Pan","year":"2025","unstructured":"Pan J, Liang J, Li Y, Chen S, Deng A, Liu L, Fu G, Lv X. Composite quantitative structural magnetic resonance imaging-based risk scoring model for predicting radiation-induced temporal lobe necrosis in nasopharyngeal carcinoma: a novel risk stratification model. Radiat Oncol. 2025;20(1):160.","journal-title":"Radiat Oncol"},{"issue":"1","key":"999_CR123","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/09622802231215801","volume":"33","author":"J Park","year":"2024","unstructured":"Park J, Hu W, Jin IH, Liu H, Zang Y. A Bayesian adaptive biomarker stratified phase II randomized clinical trial design for radiotherapies with competing risk survival outcomes. Stat Methods Med Res. 2024;33(1):80\u201395.","journal-title":"Stat Methods Med Res"},{"issue":"20","key":"999_CR124","doi-asserted-by":"publisher","first-page":"18253","DOI":"10.1007\/s00432-023-05499-z","volume":"149","author":"X Zhang","year":"2023","unstructured":"Zhang X, Cai X, Yan C. Opportunities and challenges in combining immunotherapy and radiotherapy in esophageal cancer. J Cancer Res Clin Oncol. 2023;149(20):18253\u201370.","journal-title":"J Cancer Res Clin Oncol"},{"key":"999_CR125","doi-asserted-by":"crossref","unstructured":"Master R, Rubin N, Sampson J, Yadav KK, Pandita S, Sabbagh A, Krishnan A, Silva PJ, Ramos KS, Gregoire V et al. Advances in artificial intelligence for glioblastoma radiotherapy planning and treatment. Cancers (Basel). 2025;17(23):3762.","DOI":"10.3390\/cancers17233762"},{"issue":"10","key":"999_CR126","doi-asserted-by":"publisher","first-page":"6555","DOI":"10.21037\/qims-23-229","volume":"13","author":"N Xu","year":"2023","unstructured":"Xu N, Wu D, Gao J, Jiang H, Li Q, Bao S, Luo Y, Zhou Q, Liao C, Yang J. The effect of tumor vascular remodeling and immune microenvironment activation induced by radiotherapy: quantitative evaluation with magnetic resonance\/photoacoustic dual-modality imaging. Quant Imaging Med Surg. 2023;13(10):6555\u201370.","journal-title":"Quant Imaging Med Surg"},{"issue":"2","key":"999_CR127","doi-asserted-by":"publisher","first-page":"591","DOI":"10.21037\/tlcr-2025-57","volume":"14","author":"Y Yang","year":"2025","unstructured":"Yang Y, Liu T, Mi S, Liu X, Jabbour SK, Liang N, Deng G, Hu P, Zhang J. Radiotherapy as salvage therapy and an adjunct to immunotherapy: exploring local and abscopal mechanisms to overcome immunotherapy resistance: a narrative review. Transl Lung Cancer Res. 2025;14(2):591\u2013606.","journal-title":"Transl Lung Cancer Res"},{"issue":"3","key":"999_CR128","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3892\/or.2020.7679","volume":"44","author":"DD Xu","year":"2020","unstructured":"Xu DD, Ding M, Tong P, Chong YY, Gu WY, Li Y, Fang XJ, Li N. Synergistic effects of low\u2013dose chemotherapy and T cells in renal cell carcinoma. Oncol Rep. 2020;44(3):897\u2013908.","journal-title":"Oncol Rep"},{"issue":"2","key":"999_CR129","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00262-019-02460-3","volume":"69","author":"M Hader","year":"2020","unstructured":"Hader M, Frey B, Fietkau R, Hecht M, Gaipl US. Immune biological rationales for the design of combined radio- and immunotherapies. Cancer Immunol Immunother. 2020;69(2):293\u2013306.","journal-title":"Cancer Immunol Immunother"},{"key":"999_CR130","doi-asserted-by":"crossref","unstructured":"Su NW, Chen YJ. Metronomic Therapy in Oral Squamous Cell Carcinoma. J Clin Med. 2021;10(13):2818.","DOI":"10.3390\/jcm10132818"},{"key":"999_CR131","doi-asserted-by":"publisher","first-page":"117822342210867","DOI":"10.1177\/11782234221086728","volume":"16","author":"MA Askar","year":"2022","unstructured":"Askar MA, El-Nashar HA, Al-Azzawi MA, Rahman SSA, Elshawi OE. Synergistic Effect of Quercetin Magnetite Nanoparticles and Targeted Radiotherapy in Treatment of Breast Cancer. Breast Cancer (Auckl). 2022;16:11782234221086728.","journal-title":"Breast Cancer (Auckl)"},{"issue":"18","key":"999_CR132","doi-asserted-by":"publisher","first-page":"e2007910","DOI":"10.1002\/adma.202007910","volume":"33","author":"L Sun","year":"2021","unstructured":"Sun L, Shen F, Tian L, Tao H, Xiong Z, Xu J, Liu Z. ATP-Responsive Smart Hydrogel Releasing Immune Adjuvant Synchronized with Repeated Chemotherapy or Radiotherapy to Boost Antitumor Immunity. Adv Mater. 2021;33(18):e2007910.","journal-title":"Adv Mater"},{"key":"999_CR133","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.2147\/IJN.S461701","volume":"19","author":"C He","year":"2024","unstructured":"He C, Guo Y, Zhou N, Wang Z, Liu T, Xu X, Wang F, Zhu H, Yang Z, Yang X, et al. Construction and Application of a PD-L1-Targeted Multimodal Diagnostic and Dual-Functional Theranostics Nanoprobe. Int J Nanomed. 2024;19:5479\u201392.","journal-title":"Int J Nanomed"},{"issue":"4","key":"999_CR134","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamaoncol.2019.6584","volume":"6","author":"J Martin-Broto","year":"2020","unstructured":"Martin-Broto J, Hindi N, Lopez-Pousa A, Peinado-Serrano J, Alvarez R, Alvarez-Gonzalez A, Italiano A, Sargos P, Cruz-Jurado J, Isern-Verdum J, et al. Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1\/2 Clinical Trial. JAMA Oncol. 2020;6(4):535\u201341.","journal-title":"JAMA Oncol"},{"key":"999_CR135","doi-asserted-by":"publisher","first-page":"1274487","DOI":"10.3389\/fonc.2023.1274487","volume":"13","author":"S Zhou","year":"2023","unstructured":"Zhou S, Wang C, Shen L, Wang Y, Zhang H, Wu R, Wang Y, Chen Y, Xuan Y, Xia F, et al. Regorafenib alone or in combination with high\/low-dose radiotherapy plus toripalimab as third-line treatment in patients with metastatic colorectal cancer: protocol for a prospective, randomized, controlled phase II clinical trial (SLOT). Front Oncol. 2023;13:1274487.","journal-title":"Front Oncol"},{"issue":"2","key":"999_CR136","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","volume":"23","author":"JD Schoenfeld","year":"2022","unstructured":"Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022;23(2):279\u201391.","journal-title":"Lancet Oncol"},{"issue":"4","key":"999_CR137","doi-asserted-by":"publisher","first-page":"e049119","DOI":"10.1136\/bmjopen-2021-049119","volume":"12","author":"EM Hudson","year":"2022","unstructured":"Hudson EM, Noutch S, Brown S, Adapala R, Bach SP, Burnett C, Burrage A, Gilbert A, Hawkins M, Howard D, et al. A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial. BMJ Open. 2022;12(4):e049119.","journal-title":"BMJ Open"},{"issue":"1","key":"999_CR138","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.1038\/s41467-023-43462-1","volume":"14","author":"S Li","year":"2023","unstructured":"Li S, Li K, Wang K, Yu H, Wang X, Shi M, Liang Z, Yang Z, Hu Y, Li Y, et al. Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8(+) exhausted-like T cells. Nat Commun. 2023;14(1):7709.","journal-title":"Nat Commun"},{"issue":"6","key":"999_CR139","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/ijc.34801","volume":"28","author":"JH Koo","year":"2022","unstructured":"Zhou L, Liu Y, Wu Y, Yang X, Kong FS, Lu Y, Xue J. Low-dose radiation therapy mobilizes antitumorimmunity: new findings and future perspectives. Int J Cancer. 2024;154(7):1143\u201357. https:\/\/doi.org\/10.1002\/ijc.34801","journal-title":"Trends Mol Med"},{"issue":"7","key":"999_CR140","doi-asserted-by":"publisher","first-page":"166789","DOI":"10.1016\/j.bbadis.2023.166789","volume":"1869","author":"J Wang","year":"2023","unstructured":"Wang J, Zhang J, Wen W, Wang F, Wu M, Chen D, Yu J. Exploring low-dose radiotherapy to overcome radio-immunotherapy resistance. Biochim Biophys Acta Mol Basis Dis. 2023;1869(7):166789.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"3","key":"999_CR141","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.semradonc.2024.04.002","volume":"34","author":"MT McMillan","year":"2024","unstructured":"McMillan MT, Khan AJ, Powell SN, Humm J, Deasy JO, Haimovitz-Friedman A. Spatially Fractionated Radiotherapy in the Era of Immunotherapy. Semin Radiat Oncol. 2024;34(3):276\u201383.","journal-title":"Semin Radiat Oncol"},{"key":"999_CR142","doi-asserted-by":"publisher","first-page":"1580513","DOI":"10.3389\/fonc.2025.1580513","volume":"15","author":"F Yang","year":"2025","unstructured":"Yang F, Wu J, Orlandini LC, Li H, Wang X. Proton minibeam radiotherapy: a review. Front Oncol. 2025;15:1580513.","journal-title":"Front Oncol"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00999-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00999-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00999-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:01:47Z","timestamp":1791572507000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00999-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":142,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["999"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00999-9","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"29 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study does not involve human participants or animal subjects. Therefore, ethical approval and informed consent are not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"133"}}